Additional information
| Active substance | Arimistane |
|---|---|
| Trade name | Not commercially available as a medication |
| Side effects | Potential hormonal imbalances, risk of joint discomfort, and potential impact on lipid profiles |
| Effects | Increased testosterone levels, decreased estrogen levels |
| Dosage (sports) | 50-75 mg per day |
| Dosage (medical) | Not typically used for medical purposes |
| Half-life | 48 hours |
| Main action | Inhibition of aromatase enzyme, reducing estrogen synthesis |
| Substance class | Steroidal aromatase inhibitor |
| Formula | C19H24O2 |
| Chemical name | Androsta-3,5-diene-7,17-dione |
| Storage conditions | Store in a cool, dry place away from light |
| Blood pressure | Can potentially increase if water retention occurs |
| WAREHOUSE | International Warehouse 3 |
| Also known as | Arimistane |
| Lab Test | Testosterone and estrogen levels, liver function tests |
| Aromatization | No |
| Hepatotoxicity | No |
| HBR | No |
| Water Retention | No |
| Acne | No |
| Dosage | 50 mg/day |
| Classification | Aromatase Inhibitor |
| Active Half-Life | 2-4 hours |
| Use in sports | Used as an ancillary compound to manage estrogen levels in anabolic steroid cycles |
| Manufacturer | Ultima Pharmaceuticals |
